Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance

References

• Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I, Delabesse E, Sarry A, Laurent G, Attal M, et al Improved outcome for AML patients over the years 2000-2014. Blood Cancer J. 2017;7(12):p. 635. doi:10.1038/s41408-017-0011-1.
   PubMed Web of Science ®Google Scholar
• Döhner H, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):p. 424–9.
   PubMed Web of Science ®Google Scholar
• Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, Sinnige H, Hodossy B, Graux C, Kooy RVM, et al.. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133(13):1457–1464. doi:10.1182/blood-2018-10-879866.
   PubMed Web of Science ®Google Scholar
• Wei AH, et al.. The QUAZAR AML-001 Maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Washington (DC): American Society of Hematology; 2019
   Google Scholar
• Brune M, et al.. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108(1):88–96. doi:10.1182/blood-2005-10-4073.
   PubMed Web of Science ®Google Scholar
• Martner A, Thorén FB, Aurelius J, Söderholm J, Brune M, Hellstrand K. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Rev Hematol. 2010;3(4):381–391. doi:10.1586/ehm.10.30.
   PubMed Web of Science ®Google Scholar
• Martner A, Thorén FB, Aurelius J, Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Rev. 2013;27(5):209–216. doi:10.1016/j.blre.2013.06.006.
   PubMed Web of Science ®Google Scholar
• Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018;43:8–15. doi:10.1016/j.cytogfr.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Turzanski J, et al.. Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia. 2004;18(10):1662–1670. doi:10.1038/sj.leu.2403457.
   PubMed Web of Science ®Google Scholar
• Bruserud O. Effects of endogenous interleukin 1 on blast cells derived from acute myelogenous leukemia patients. Leuk Res. 1996;20(1):65–73. doi:10.1016/0145-2126(95)00112-3.
   PubMed Web of Science ®Google Scholar
• Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, et al.. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18(13):3204–3218. doi:10.1016/j.celrep.2017.03.018.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun X, Yuan S, Hou S, Guo T, Chu Y, Pang T, Luo HR, Yuan W, Wang X, et al.. Interleukin-1β inhibits normal hematopoietic expansion and promotes acute myeloid leukemia progression via the bone marrow niche. Cytotherapy. 2020;22(3):127–134. doi:10.1016/j.jcyt.2020.01.001.
   PubMed Web of Science ®Google Scholar
• Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90:1345–1364.
   PubMed Web of Science ®Google Scholar
• Wyszynski RW, Gibbs BF, Varani L, Iannotta D, Sumbayev VV. Interleukin-1 beta induces the expression and production of stem cell factor by epithelial cells: crucial involvement of the PI-3K/mTOR pathway and HIF-1 transcription complex. Cell Mol Immunol. 2016;13(1):47–56. doi:10.1038/cmi.2014.113.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Yoon JH, Song KS. Chrysin inhibited stem cell factor (SCF)/c-Kit complex-induced cell proliferation in human myeloid leukemia cells. Biochem Pharmacol. 2007;74(2):215–225. doi:10.1016/j.bcp.2007.04.011.
   PubMed Web of Science ®Google Scholar
• Tao M, et al.. SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine. 2000;12(6):699–707. doi:10.1006/cyto.2000.0666.
   PubMed Web of Science ®Google Scholar
• Fields JK, Günther S, Sundberg EJ. Structural basis of IL-1 family cytokine signaling. Front Immunol. 2019;10:1412. doi:10.3389/fimmu.2019.01412.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8–27.
   PubMed Web of Science ®Google Scholar
• Loo YM, Gale M Jr.. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680–692. doi:10.1016/j.immuni.2011.05.003.
   PubMed Web of Science ®Google Scholar
• Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10(3):241–247. doi:10.1038/ni.1703.
   PubMed Web of Science ®Google Scholar
• Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature. 1997;386(6621):194–200. doi:10.1038/386194a0.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al.. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914.
   PubMed Web of Science ®Google Scholar
• Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, Dinarello CA, Voronov E, Apte RN. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116(4):1361–1369. doi:10.1073/pnas.1812266115.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50(4):778–795. doi:10.1016/j.immuni.2019.03.012.
   PubMed Web of Science ®Google Scholar
• Lee P-H, Yamamoto TN, Gurusamy D, Sukumar M, Yu Z, Hu-Li J, Kawabe T, Gangaplara A, Kishton RJ, Henning AN, et al.. Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells. J Exp Med. 2019;216(11):2619–2634. doi:10.1084/jem.20181218.
   PubMed Web of Science ®Google Scholar
• Aggen DH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, Chaimowitz MG, Lopez-Bujanda ZA, Spina CS, Hawley JE, et al.. Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses. Clin Cancer Res. 2021;27(2):608–621. doi:10.1158/1078-0432.CCR-20-1610.
   PubMed Web of Science ®Google Scholar
• Sander FE, Rydström A, Bernson E, Kiffin R, Riise R, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, et al.. Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. Oncotarget. 2016;7(7):7586–7596. doi:10.18632/oncotarget.7210.
   PubMedGoogle Scholar
• Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunology. 2016;5(1):e1041701. doi:10.1080/2162402X.2015.1041701.
   PubMed Web of Science ®Google Scholar
• Martner A, Rydström A, Riise RE, Aurelius J, Brune M, Foà R, Hellstrand K, Thorén FB. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget. 2015;6(40):42569–42574. doi:10.18632/oncotarget.5559.
   PubMedGoogle Scholar
• Sander FE, et al.. Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunol Immunother. 2017;66(4):1473–1484. doi:10.1007/s00262-017-2040-9.
   PubMed Web of Science ®Google Scholar
• Bai B, Yang Y, Wang Q, Li M, Tian C, Liu Y, Aung LHH, Li P-F, Yu T, Chu X-M, et al.. NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 2020;11(9):776. doi:10.1038/s41419-020-02985-x.
   PubMed Web of Science ®Google Scholar
• Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;11(9):210–215. doi:10.1038/nri2725.
   Web of Science ®Google Scholar
• Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, Thorén FB, Ståhlberg A, Hermodsson S, Hellstrand K, et al.. Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase. J Immunol. 2015;194(10):5014–5021. doi:10.4049/jimmunol.1402991.
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol. 1994;153:4940–4947.
   PubMed Web of Science ®Google Scholar
• Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol. 1996;43(1):9–15. doi:10.1046/j.1365-3083.1996.d01-14.x.
   PubMed Web of Science ®Google Scholar
• Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, Martner A, Hellstrand K, Thorén FB. The HLA-B −21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood. 2019;133(13):1479–1488. doi:10.1182/blood-2018-09-874990.
   PubMed Web of Science ®Google Scholar
• Bernson E, Hallner A, Sander FE, Nicklasson M, Nilsson MS, Christenson K, Aydin E, Liljeqvist J-Å, Brune M, Foà R, et al.. Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. Cancer Immunol Res. 2018;6(9):1110–1119. doi:10.1158/2326-6066.CIR-17-0711.
   PubMed Web of Science ®Google Scholar
• Branco A, Yoshikawa FSY, et al.. Role of histamine in modulating the immune response and inflammation. Mediators Inflamm. 2018;2018:9524075. Pietrobon, A J., Sato, M N.. doi:10.1155/2018/9524075.
   PubMed Web of Science ®Google Scholar
• Dohlsten M, et al.. Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes. Scand J Immunol. 1988;27(5):527–532. doi:10.1111/j.1365-3083.1988.tb02379.x.
   PubMed Web of Science ®Google Scholar
• Nishibori M, Takahashi HK, Mori S. The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. J Pharmacol Sci. 2003;92(1):7–12. doi:10.1254/jphs.92.7.
   PubMed Web of Science ®Google Scholar
• Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood. 2000;96(5):1961–1968. doi:10.1182/blood.V96.5.1961.
   PubMed Web of Science ®Google Scholar
• Aydin E, Johansson J, Nazir FH, Hellstrand K, Martner A. Role of NOX2-derived reactive oxygen species in NK cell-mediated control of murine melanoma metastasis. Cancer Immunol Res. 2017;5(9):804–811. doi:10.1158/2326-6066.CIR-16-0382.
   PubMed Web of Science ®Google Scholar
• Frei R, Ferstl R, Konieczna P, Ziegler M, Simon T, Rugeles TM, Mailand S, Watanabe T, Lauener R, Akdis CA, et al.. Histamine receptor 2 modifies dendritic cell responses to microbial ligands. J Allergy Clin Immunol. 2013;132(1):194–204. doi:10.1016/j.jaci.2013.01.013.
   PubMed Web of Science ®Google Scholar
• Yang XD, Ai W, Asfaha S, Bhagat G, Friedman RA, Jin G, Park H, Shykind B, Diacovo TG, Falus A, et al.. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med. 2011;17(1):87–95. doi:10.1038/nm.2278.
   PubMed Web of Science ®Google Scholar
• Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol. 1996;156:2558–2565.
   PubMed Web of Science ®Google Scholar
• Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31(2):331–341. doi:10.1016/j.immuni.2009.08.001.
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179–189. doi:10.1016/j.immuni.2006.01.001.
   PubMed Web of Science ®Google Scholar
• Kramer F, Torzewski J, Kamenz J, Veit K, Hombach V, Dedio J, Ivashchenko Y. Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop. Mol Immunol. 2008;45(9):2678–2689. doi:10.1016/j.molimm.2007.12.017.
   PubMed Web of Science ®Google Scholar
• Kordella C, Lamprianidou E, Kotsianidis I. Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter. Front Oncol. 2021;11:650473. doi:10.3389/fonc.2021.650473.
   PubMed Web of Science ®Google Scholar
• Moudra A, Hubackova S, Machalova V, Vancurova M, Bartek J, Reinis M, Hodny Z, Jonasova A. Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine. Oncoimmunology. 2016;5(10):e1183860. doi:10.1080/2162402X.2016.1183860.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Oreffo ROC, Gibson MB, Goldring MB, Roach HI. DNA demethylation at specific CpG sites in the IL1B promoter in response to inflammatory cytokines in human articular chondrocytes. Arthritis Rheum. 2009;60(11):3303–3313. doi:10.1002/art.24882.
   PubMed Web of Science ®Google Scholar
• Martner A, Aydin E, Hellstrand K. NOX2 in autoimmunity tumor growth and metastasis. J Pathol. 2019;247(2):151–154. doi:10.1002/path.5175.
   PubMed Web of Science ®Google Scholar
• Singh A, Singh V, Tiwari RL, Chandra T, Kumar A, Dikshit M, Barthwal MK. The IRAK-ERK-p67phox-Nox-2 axis mediates TLR4, 2-induced ROS production for IL-1β transcription and processing in monocytes. Cell Mol Immunol. 2016;13(6):745–763. doi:10.1038/cmi.2015.62.
   PubMed Web of Science ®Google Scholar
• Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674–677. doi:10.1126/science.1156995.
   PubMed Web of Science ®Google Scholar
• Gabelloni ML, et al.. NADPH oxidase derived reactive oxygen species are involved in human neutrophil IL-1β secretion but not in inflammasome activation. Eur J Immunol. 2013;43(12):3324–3335. doi:10.1002/eji.201243089.
   PubMed Web of Science ®Google Scholar
• Liu N, Wu Y, Wen X, Li P, Lu F, Shang H. Chronic stress promotes acute myeloid leukemia progression through HMGB1/NLRP3/IL-1β signaling pathway. J Mol Med (Berl). 2021;99(3):403–414. doi:10.1007/s00109-020-02011-9.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–3732. doi:10.1182/blood-2010-07-273417.
   PubMed Web of Science ®Google Scholar
• Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, Ghigo D. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab. 2008;9(8):686–696. doi:10.2174/138920008786049285.
   PubMed Web of Science ®Google Scholar
• Massart C, Giusti N, Beauwens R, Dumont JE, Miot F, Sande JV. Diphenyleneiodonium, an inhibitor of NOXes and DUOXes, is also an iodide-specific transporter. FEBS Open Bio. 2013;4(1):55–59. doi:10.1016/j.fob.2013.11.007.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, Ridker P, Lorenzatti A, Krum H, Varigos J, et al.. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–1842. doi:10.1016/S0140-6736(17)32247-X.
   PubMed Web of Science ®Google Scholar